Expert Interview
A Second Look: Discussing Gilead’s Livdelzi (seladelpar) recently approved for treatment of primary biliary cholangitis (PBC) in patients who have an inadequate response to UDCA or are unable to tolerate UDCA
Ticker(s): GILDInstitution: University of Illinois Chicago
- Hepatologist and Gastroenterologist at University of Illinois practicing for over 13 years.
- Currently manages 30 patients with PBC.
- Assistant Professor of Medicine, Division of Gastroenterology and Hepatology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
